logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical strikes deal with Asterion Cannabis for medical CBD

Stephen Van Deventer, chairman and CEO of PreveCeutical Medical Inc (CNSX:PREV), discusses with Proactive's Andrew Scott the deal they've struck with private firm Asterion Cannabis Inc to develop medical CBD (cannabidiol) products.

In the companies’ sights via the joint venture are tablets, transdermal patches and other jointly evaluated products aimed at treating chronic pain, inflammation, epilepsy,  anxiety disorders and others.

Quick facts: PreveCeutical Medical Inc.

Price: 0.015 CAD

CSE:PREV
Market: CSE
Market Cap: $5.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read